BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 2015;80:193-9. [PMID: 25731075 DOI: 10.1111/bcp.12618] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Edvinsson JCA, Viganò A, Alekseeva A, Alieva E, Arruda R, De Luca C, D'Ettore N, Frattale I, Kurnukhina M, Macerola N, Malenkova E, Maiorova M, Novikova A, Řehulka P, Rapaccini V, Roshchina O, Vanderschueren G, Zvaune L, Andreou AP, Haanes KA; European Headache Federation School of Advanced Studies (EHF-SAS). The fifth cranial nerve in headaches. J Headache Pain 2020;21:65. [PMID: 32503421 DOI: 10.1186/s10194-020-01134-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
2 Blumenfeld A, Durham PL, Feoktistov A, Hay DL, Russo AF, Turner I. Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor. Neurol Ther 2021. [PMID: 34076848 DOI: 10.1007/s40120-021-00250-7] [Reference Citation Analysis]
3 Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets 2020;24:91-100. [PMID: 32003253 DOI: 10.1080/14728222.2020.1724285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
4 Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Headache 2020;60:1340-50. [PMID: 32573795 DOI: 10.1111/head.13862] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Giamberardino MA, Affaitati G, Costantini R, Cipollone F, Martelletti P. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res 2017;10:2751-60. [PMID: 29263689 DOI: 10.2147/JPR.S128143] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
6 Al-Hassany L, MaassenVanDenBrink A. Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine. Curr Opin Neurol 2021;34:330-8. [PMID: 33852525 DOI: 10.1097/WCO.0000000000000932] [Reference Citation Analysis]
7 Frederiksen SD, Warfvinge K, Ohlsson L, Edvinsson L. Expression of Pituitary Adenylate Cyclase-activating Peptide, Calcitonin Gene-related Peptide and Headache Targets in the Trigeminal Ganglia of Rats and Humans. Neuroscience 2018;393:319-32. [DOI: 10.1016/j.neuroscience.2018.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Jay GW, Barkin RL. Primary Headache Disorders Part I- Migraine and the Trigeminal Autonomic Cephalalgias. Disease-a-Month 2017;63:308-38. [DOI: 10.1016/j.disamonth.2017.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A; Italian chronic migraine group. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 2019;20:92. [PMID: 31470791 DOI: 10.1186/s10194-019-1038-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
10 Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P. Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Review of Neurotherapeutics 2016;16:1217-27. [DOI: 10.1080/14737175.2016.1200973] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
11 Vécsei L, Lukács M, Tajti J, Fülöp F, Toldi J, Edvinsson L. The Therapeutic Impact of New Migraine Discoveries. Curr Med Chem 2019;26:6261-81. [PMID: 29848264 DOI: 10.2174/0929867325666180530114534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. BioDrugs 2017;31:487-501. [DOI: 10.1007/s40259-017-0250-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
13 Ong JJY, Wei DY, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs 2018;78:411-37. [PMID: 29396834 DOI: 10.1007/s40265-018-0865-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 12.3] [Reference Citation Analysis]
14 Tietjen GE, Buse DC, Collins SA. Childhood Maltreatment in the Migraine Patient. Curr Treat Options Neurol 2016;18:31. [PMID: 27194425 DOI: 10.1007/s11940-016-0415-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
15 Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, Guglielmetti M, Koniari C, Mavridis T, Vaikjärv M, Verhagen I, Verzina A, Zick B, Martelletti P, Sacco S; European Headache Federation School of Advanced Studies (EHF-SAS). CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 2019;20:27. [PMID: 30866804 DOI: 10.1186/s10194-019-0979-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
16 Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, Tonin P, Corasaniti MT. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies. Front Pharmacol 2019;10:363. [PMID: 31024319 DOI: 10.3389/fphar.2019.00363] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
17 Dux M, Rosta J, Messlinger K. TRP Channels in the Focus of Trigeminal Nociceptor Sensitization Contributing to Primary Headaches. Int J Mol Sci 2020;21:E342. [PMID: 31948011 DOI: 10.3390/ijms21010342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
18 Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med 2016;11:1045-57. [PMID: 27339365 DOI: 10.1007/s11739-016-1489-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
19 Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. Clinical Neurology and Neurosurgery 2020;195:105900. [DOI: 10.1016/j.clineuro.2020.105900] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhao LP, Liu L, Pei P, Qu ZY, Zhu YP, Wang LP. Electroacupuncture at Fengchi (GB20) inhibits calcitonin gene-related peptide expression in the trigeminovascular system of a rat model of migraine. Neural Regen Res 2017;12:804-11. [PMID: 28616038 DOI: 10.4103/1673-5374.206652] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
21 Lundblad C, Haanes KA, Grände G, Edvinsson L. Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. J Headache Pain 2015;16:91. [PMID: 26512021 DOI: 10.1186/s10194-015-0575-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
22 Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Curr Treat Options Neurol 2017;19:27. [PMID: 28653227 DOI: 10.1007/s11940-017-0463-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 15.6] [Reference Citation Analysis]
23 Taylor FR. CGRP, Amylin, Immunology, and Headache Medicine: Headache. Headache: The Journal of Head and Face Pain 2019;59:131-50. [DOI: 10.1111/head.13432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
24 Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 2017;158:543-59. [PMID: 28301400 DOI: 10.1097/j.pain.0000000000000831] [Cited by in Crossref: 185] [Cited by in F6Publishing: 163] [Article Influence: 37.0] [Reference Citation Analysis]
25 Ishida K, Tanaka S, Shen D, Matsui S, Fuseya S, Shindo T, Kawamata M. Calcitonin gene-related peptide is not involved in neuropathic pain induced by partial sciatic nerve ligation in mice. Neuroscience Letters 2022;778:136615. [DOI: 10.1016/j.neulet.2022.136615] [Reference Citation Analysis]
26 Piechal A, Domitrz I, Kurkowska-Jastrzębska I, Mirowska-Guzel D. Are antimigraine drugs that influence CGRP levels justified? Pharmacol Rep 2019;71:624-35. [PMID: 31181379 DOI: 10.1016/j.pharep.2019.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Avilés-Rosas VH, Rivera-Mancilla E, Marichal-Cancino BA, Manrique-Maldonado G, Altamirano-Espinoza AH, Maassen Van Den Brink A, Villalón CM. Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol 2017;174:2001-14. [PMID: 28369749 DOI: 10.1111/bph.13799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
28 Szok D, Csáti A, Vécsei L, Tajti J. Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. Toxins (Basel) 2015;7:2659-73. [PMID: 26193319 DOI: 10.3390/toxins7072659] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Maassenvandenbrink A, Meijer J, Villalón CM, Ferrari MD. Wiping Out CGRP: Potential Cardiovascular Risks. Trends in Pharmacological Sciences 2016;37:779-88. [DOI: 10.1016/j.tips.2016.06.002] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 19.3] [Reference Citation Analysis]
30 Edvinsson L. The Journey to Establish CGRP as a Migraine Target: A Retrospective View. Headache 2015;55:1249-55. [PMID: 26368117 DOI: 10.1111/head.12656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
31 Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17:75-83. [PMID: 29174963 DOI: 10.1016/s1474-4422(17)30405-2] [Cited by in Crossref: 106] [Cited by in F6Publishing: 32] [Article Influence: 21.2] [Reference Citation Analysis]
32 Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:382-90. [PMID: 26879279 DOI: 10.1016/S1474-4422(16)00019-3] [Cited by in Crossref: 217] [Cited by in F6Publishing: 95] [Article Influence: 36.2] [Reference Citation Analysis]
33 Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A; European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18:96. [PMID: 28948500 DOI: 10.1186/s10194-017-0807-1] [Cited by in Crossref: 124] [Cited by in F6Publishing: 88] [Article Influence: 24.8] [Reference Citation Analysis]
34 Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache 2018;58 Suppl 1:33-47. [PMID: 29697153 DOI: 10.1111/head.13305] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 13.3] [Reference Citation Analysis]
35 Pellesi L, Guerzoni S, Pini LA. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clin Pharmacol Drug Dev 2017;6:534-47. [PMID: 28409893 DOI: 10.1002/cpdd.345] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
36 Filiz A, Tepe N, Eftekhari S, Boran HE, Dilekoz E, Edvinsson L, Bolay H. CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia 2019;39:354-65. [PMID: 28971699 DOI: 10.1177/0333102417735845] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
37 Hay DL, Walker CS. CGRP and its receptors. Headache 2017;57:625-36. [PMID: 28233915 DOI: 10.1111/head.13064] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
38 Booe JM, Warner ML, Roehrkasse AM, Hay DL, Pioszak AA. Probing the Mechanism of Receptor Activity-Modifying Protein Modulation of GPCR Ligand Selectivity through Rational Design of Potent Adrenomedullin and Calcitonin Gene-Related Peptide Antagonists. Mol Pharmacol 2018;93:355-67. [PMID: 29363552 DOI: 10.1124/mol.117.110916] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
39 Guerrero-Toro C, Koroleva K, Ermakova E, Gafurov O, Abushik P, Tavi P, Sitdikova G, Giniatullin R. Testing the Role of Glutamate NMDA Receptors in Peripheral Trigeminal Nociception Implicated in Migraine Pain. Int J Mol Sci 2022;23:1529. [PMID: 35163452 DOI: 10.3390/ijms23031529] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Baranowsky A, Appelt J, Kleber C, Lange T, Ludewig P, Jahn D, Pandey P, Keller D, Rose T, Schetler D, Braumüller S, Huber-Lang M, Tsitsilonis S, Yorgan T, Frosch KH, Amling M, Schinke T, Keller J. Procalcitonin Exerts a Mediator Role in Septic Shock Through the Calcitonin Gene-Related Peptide Receptor. Crit Care Med 2021;49:e41-52. [PMID: 33196529 DOI: 10.1097/CCM.0000000000004731] [Reference Citation Analysis]
41 Wrobel Goldberg S, Silberstein SD. Targeting CGRP: A New Era for Migraine Treatment. CNS Drugs 2015;29:443-52. [PMID: 26138383 DOI: 10.1007/s40263-015-0253-z] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
42 Li Puma S, Landini L, Macedo SJ Jr, Seravalli V, Marone IM, Coppi E, Patacchini R, Geppetti P, Materazzi S, Nassini R, De Logu F. TRPA1 mediates the antinociceptive properties of the constituent of Crocus sativus L., safranal. J Cell Mol Med 2019;23:1976-86. [PMID: 30636360 DOI: 10.1111/jcmm.14099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Johnson KW, Morin SM, Wroblewski VJ, Johnson MP. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [ 125 I] galcanezumab in male rats. Cephalalgia 2019;39:1241-8. [DOI: 10.1177/0333102419844711] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
44 Souza Monteiro de Araujo D, Nassini R, Geppetti P, De Logu F. TRPA1 as a therapeutic target for nociceptive pain. Expert Opin Ther Targets 2020;24:997-1008. [PMID: 32838583 DOI: 10.1080/14728222.2020.1815191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
45 Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1091-100. [PMID: 26432181 DOI: 10.1016/S1474-4422(15)00245-8] [Cited by in Crossref: 166] [Cited by in F6Publishing: 80] [Article Influence: 23.7] [Reference Citation Analysis]
46 Benemei S, De Logu F, Li Puma S, Marone IM, Coppi E, Ugolini F, Liedtke W, Pollastro F, Appendino G, Geppetti P, Materazzi S, Nassini R. The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel. Br J Pharmacol 2017;174:2897-911. [PMID: 28622417 DOI: 10.1111/bph.13917] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
47 Barbanti P, Egeo G, Mitsikostas DD. Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number? Headache: The Journal of Head and Face Pain 2019;59:1659-61. [DOI: 10.1111/head.13635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Edvinsson L, Haanes KA. Views on migraine pathophysiology: Where does it start? Neurol Clin Neurosci 2020;8:120-7. [DOI: 10.1111/ncn3.12356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Joshi S, Tepper SJ, Lucas S, Rasmussen S, Nelson R. A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management. Headache 2021;61:838-53. [PMID: 34214182 DOI: 10.1111/head.14135] [Reference Citation Analysis]
50 Mehkri Y, Hanna C, Sriram S, Lucke-Wold B, Johnson RD, Busl K. Calcitonin gene-related peptide and neurologic injury: An emerging target for headache management. Clin Neurol Neurosurg 2022;220:107355. [PMID: 35785661 DOI: 10.1016/j.clineuro.2022.107355] [Reference Citation Analysis]
51 Ng CYH, Tan BYQ, Teo YN, Teo YH, Syn NLX, Leow AST, Ho JSY, Chan MY, Wong RCC, Chai P, Chan ACY, Sharma VK, Yeo LLL, Sia CH, Ong JJY. Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis. J Neurol 2022. [PMID: 34997286 DOI: 10.1007/s00415-021-10930-x] [Reference Citation Analysis]
52 Wang Y, Tye AE, Zhao J, Ma D, Raddant AC, Bu F, Spector BL, Winslow NK, Wang M, Russo AF. Induction of calcitonin gene-related peptide expression in rats by cortical spreading depression. Cephalalgia 2019;39:333-41. [PMID: 27919019 DOI: 10.1177/0333102416678388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
53 Casili G, Lanza M, Filippone A, Campolo M, Paterniti I, Cuzzocrea S, Esposito E. Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice. J Neuroinflammation 2020;17:59. [PMID: 32066464 DOI: 10.1186/s12974-020-01736-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
54 Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G, Tore F. Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats. Clin Exp Pharmacol Physiol 2018;45:536-46. [PMID: 29344989 DOI: 10.1111/1440-1681.12915] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
55 Iannone LF, Nassini R, Patacchini R, Geppetti P, De Logu F. Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief. Temperature. [DOI: 10.1080/23328940.2022.2075218] [Reference Citation Analysis]
56 Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine: CGRP and CGRP Receptors in Migraine. Headache: The Journal of Head and Face Pain 2017;57:47-55. [DOI: 10.1111/head.13081] [Cited by in Crossref: 131] [Cited by in F6Publishing: 106] [Article Influence: 26.2] [Reference Citation Analysis]
57 Urits I, Jones MR, Gress K, Charipova K, Fiocchi J, Kaye AD, Viswanath O. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. Curr Pain Headache Rep 2019;23:29. [PMID: 30874961 DOI: 10.1007/s11916-019-0768-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
58 Mason BN, Russo AF. Vascular Contributions to Migraine: Time to Revisit? Front Cell Neurosci 2018;12:233. [PMID: 30127722 DOI: 10.3389/fncel.2018.00233] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
59 Boinpally R, Jakate A, Butler M, Periclou A. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial. Pain Manag 2021. [PMID: 34898273 DOI: 10.2217/pmt-2021-0073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
60 Lukács M, Haanes KA, Majláth Z, Tajti J, Vécsei L, Warfvinge K, Edvinsson L. Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion. J Headache Pain 2015;16:564. [PMID: 26329487 DOI: 10.1186/s10194-015-0564-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
61 Eiden LE, Goosens KA, Jacobson KA, Leggio L, Zhang L. Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. ACS Pharmacol Transl Sci 2020;3:190-202. [PMID: 32296762 DOI: 10.1021/acsptsci.0c00017] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zagami AS. Treatment of the Patient with Refractory Headache. Curr Pain Headache Rep 2018;22. [DOI: 10.1007/s11916-018-0677-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Iannone LF, De Logu F, Geppetti P, De Cesaris F. The role of TRP ion channels in migraine and headache. Neurosci Lett 2022;768:136380. [PMID: 34861342 DOI: 10.1016/j.neulet.2021.136380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G. Timing and durability of response to erenumab in patients with chronic migraine. Headache 2021. [PMID: 34363708 DOI: 10.1111/head.14193] [Reference Citation Analysis]
65 Fekrazad R, Sardarian A, Azma K, Karami M, Borhani-haghighi A, Gharesi-fard B, Movahedi B. Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients. Neurol Sci 2018;39:1217-23. [DOI: 10.1007/s10072-018-3340-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
66 Loh NR, Whitehouse WP, Howells R. What is new in migraine management in children and young people? Arch Dis Child 2022:archdischild-2021-322373. [PMID: 35190383 DOI: 10.1136/archdischild-2021-322373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Lacković Z, Filipović B, Matak I, Helyes Z. Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches. Br J Pharmacol 2016;173:279-91. [PMID: 26493010 DOI: 10.1111/bph.13366] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
68 Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol 2018;14:338-50. [DOI: 10.1038/s41582-018-0003-1] [Cited by in Crossref: 290] [Cited by in F6Publishing: 251] [Article Influence: 72.5] [Reference Citation Analysis]
69 Dahri M, Tarighat-esfanjani A, Asghari-jafarabadi M, Hashemilar M. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutritional Neuroscience 2018;22:607-15. [DOI: 10.1080/1028415x.2017.1421039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
70 Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 2017;18:42. [PMID: 28389966 DOI: 10.1186/s10194-017-0750-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
71 Chan TLH, Cowan RP, Woldeamanuel YW. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis. Headache 2020;60:1489-99. [PMID: 32515018 DOI: 10.1111/head.13858] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619-6629. [PMID: 25926442 DOI: 10.1523/jneurosci.0373-15.2015] [Cited by in Crossref: 317] [Cited by in F6Publishing: 123] [Article Influence: 45.3] [Reference Citation Analysis]
73 Akhtar A. The Role of Anti-calcitonin Gene-related Peptide in Migraine and its Implication in Developing Countries: A Reasonable Option to Consider Despite Higher Cost. Cureus 2019;11:e4796. [PMID: 31396466 DOI: 10.7759/cureus.4796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 2019;39:1075-85. [PMID: 31234642 DOI: 10.1177/0333102419858355] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 15.0] [Reference Citation Analysis]
75 Maegawa H, Yoshikawa C, Usami N, Hanamoto H, Kudo C, Niwa H. Anti-calcitonin gene-related peptide antibody attenuates orofacial mechanical and heat hypersensitivities induced by infraorbital nerve injury. Biochem Biophys Res Commun 2021;569:147-53. [PMID: 34245979 DOI: 10.1016/j.bbrc.2021.07.001] [Reference Citation Analysis]
76 De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 2020;20:627-41. [PMID: 32434430 DOI: 10.1080/14737175.2020.1772758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
77 Mason BN, Kaiser EA, Kuburas A, Loomis MM, Latham JA, Garcia-Martinez LF, Russo AF. Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms. J Neurosci 2017;37:204-16. [PMID: 28053042 DOI: 10.1523/JNEUROSCI.2967-16.2016] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
78 Mungoven TJ, Henderson LA, Meylakh N. Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Front Pain Res (Lausanne) 2021;2:705276. [PMID: 35295486 DOI: 10.3389/fpain.2021.705276] [Reference Citation Analysis]
79 Cady R, Lipton RB. Qualitative Change in Migraine Prevention? Headache: The Journal of Head and Face Pain 2018;58:1092-5. [DOI: 10.1111/head.13354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Kissin I. Scientometrics of drug discovery efforts: pain-related molecular targets. Drug Des Devel Ther 2015;9:3393-404. [PMID: 26170624 DOI: 10.2147/DDDT.S85633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
81 Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother 2018;19:123-36. [PMID: 29212383 DOI: 10.1080/14656566.2017.1414182] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
82 Leroux E, Rothrock J. Triptans for Migraine Patients With Vascular Risks: New Insights, New Options. Headache: The Journal of Head and Face Pain 2019;59:1589-96. [DOI: 10.1111/head.13656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
83 Edvinsson L, Haanes KA. Identifying New Antimigraine Targets: Lessons from Molecular Biology. Trends Pharmacol Sci 2021;42:217-25. [PMID: 33495027 DOI: 10.1016/j.tips.2021.01.002] [Reference Citation Analysis]
84 Barbanti P, Aurilia C, Fofi L, Egeo G, Ferroni P. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurol Sci 2017;38:31-5. [PMID: 28527063 DOI: 10.1007/s10072-017-2907-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
85 Messlinger K, Russo AF. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia 2019;39:1661-74. [PMID: 29989427 DOI: 10.1177/0333102418786261] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
86 Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, Yoon E, Gandhi MD, Spiegelstein O, Aycardi E. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 2018;38:1960-71. [PMID: 29667896 DOI: 10.1177/0333102418771376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
87 Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C, Edvinsson L. Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience 2016;328:165-83. [PMID: 27155150 DOI: 10.1016/j.neuroscience.2016.04.046] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
88 Henson B, Hollingsworth H, Nevois E, Herndon C. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines. J Pain Palliat Care Pharmacother 2020;34:22-31. [PMID: 31763951 DOI: 10.1080/15360288.2019.1690616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Nowodworska A, van den Maagdenberg AMJM, Nistri A, Fabbretti E. In situ imaging reveals properties of purinergic signalling in trigeminal sensory ganglia in vitro. Purinergic Signal 2017;13:511-20. [PMID: 28822016 DOI: 10.1007/s11302-017-9576-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
90 Scuteri D, Bagetta G. Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab. Pharmaceuticals (Basel) 2021;14:924. [PMID: 34577624 DOI: 10.3390/ph14090924] [Reference Citation Analysis]
91 Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 2019;39:366-73. [DOI: 10.1177/0333102417736900] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
92 Papetti L, Tarantino S, Ursitti F, Moavero R, Proietti MC, Sforza G, Monte G, Ferilli MAN, Balestri M, Vigevano F, Valeriani M. From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years? Front Neurol 2022;13:935803. [DOI: 10.3389/fneur.2022.935803] [Reference Citation Analysis]
93 Rubio-Beltran E, Chan KY, Danser AJ, MaassenVanDenBrink A, Edvinsson L. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia 2020;40:357-66. [PMID: 31674221 DOI: 10.1177/0333102419884943] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
94 Rytel L, Całka J. Aspirin Administration Affects Neurochemical Characterization of Substance P-Like Immunoreactive (SP-LI) Nodose Ganglia Neurons Supplying the Porcine Stomach. Biomed Res Int 2020;2020:1049179. [PMID: 32626731 DOI: 10.1155/2020/1049179] [Reference Citation Analysis]
95 Barloese MCJ. The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications. Clin Auton Res 2018;28:315-24. [DOI: 10.1007/s10286-017-0468-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
96 King CT, Gegg CV, Hu SN, Sen Lu H, Chan BM, Berry KA, Brankow DW, Boone TJ, Kezunovic N, Kelley MR, Shi L, Xu C. Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor. ACS Pharmacol Transl Sci 2019;2:485-90. [PMID: 32259079 DOI: 10.1021/acsptsci.9b00061] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
97 Zhao J, Levy D. The CGRP receptor antagonist BIBN4096 inhibits prolonged meningeal afferent activation evoked by brief local K+ stimulation but not cortical spreading depression-induced afferent sensitization. Pain Rep 2018;3:e632. [PMID: 29430561 DOI: 10.1097/PR9.0000000000000632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
98 Pellitteri G, Pez S, Nilo A, Surcinelli A, Gigli GL, Lettieri C, Valente M. Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study. Front Neurol 2022;13:869677. [DOI: 10.3389/fneur.2022.869677] [Reference Citation Analysis]
99 Ferroni P, Barbanti P, Della-Morte D, Palmirotta R, Jirillo E, Guadagni F. Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions. Antioxid Redox Signal 2018;28:1144-83. [PMID: 28990418 DOI: 10.1089/ars.2017.7260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
100 Ashish K, Faisaluddin M, Bandyopadhyay D, Dhaduk K, Baral A. Therapeutic role of monoclonal antibodies in Migraine: A new paradigm. Eur J Intern Med 2018;57:e9-e10. [PMID: 30031595 DOI: 10.1016/j.ejim.2018.07.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 González-Hernández A, Marichal-Cancino BA, Lozano-Cuenca J, López-Canales JS, Muñoz-Islas E, Ramírez-Rosas MB, Villalón CM. Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases. Biomed Res Int 2016;2016:2056786. [PMID: 28116293 DOI: 10.1155/2016/2056786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
102 Reuter U. A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine. Headache: The Journal of Head and Face Pain 2018;58:48-59. [DOI: 10.1111/head.13302] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
103 Mehnert J, May A. Functional and structural alterations in the migraine cerebellum. J Cereb Blood Flow Metab 2019;39:730-9. [PMID: 28737061 DOI: 10.1177/0271678X17722109] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
104 Brown DG, Wobst HJ. A survey of the clinical pipeline in neuroscience. Bioorg Med Chem Lett 2022;56:128482. [PMID: 34864194 DOI: 10.1016/j.bmcl.2021.128482] [Reference Citation Analysis]
105 Messlinger K, Balcziak LK, Russo AF. Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators. J Neural Transm (Vienna) 2020;127:431-44. [PMID: 32088764 DOI: 10.1007/s00702-020-02161-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
106 De Logu F, Nassini R, Materazzi S, Carvalho Gonçalves M, Nosi D, Rossi Degl'Innocenti D, Marone IM, Ferreira J, Li Puma S, Benemei S, Trevisan G, Souza Monteiro de Araújo D, Patacchini R, Bunnett NW, Geppetti P. Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice. Nat Commun 2017;8:1887. [PMID: 29192190 DOI: 10.1038/s41467-017-01739-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 14.4] [Reference Citation Analysis]
107 Saklani P, Khan H, Gupta S, Kaur A, Singh TG. Neuropeptides: Potential neuroprotective agents in ischemic injury. Life Sci 2022;288:120186. [PMID: 34852271 DOI: 10.1016/j.lfs.2021.120186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
108 Na H, Gan Q, Mcparland L, Yang JB, Yao H, Tian H, Zhang Z, Qiu WQ. Characterization of the effects of calcitonin gene-related peptide receptor antagonist for Alzheimer's disease. Neuropharmacology 2020;168:108017. [PMID: 32113968 DOI: 10.1016/j.neuropharm.2020.108017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, Vollesen AL, Lampl C, Ashina M; School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain 2017;18:103. [PMID: 29019093 DOI: 10.1186/s10194-017-0811-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
110 van Hoogstraten WS, MaassenVanDenBrink A. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. J Headache Pain 2019;20:54. [PMID: 31096904 DOI: 10.1186/s10194-019-1007-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
111 Jiang L, Wang Y, Xu Y, Ma D, Wang M. The Transient Receptor Potential Ankyrin Type 1 Plays a Critical Role in Cortical Spreading Depression. Neuroscience 2018;382:23-34. [PMID: 29719223 DOI: 10.1016/j.neuroscience.2018.04.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
112 Basutkar RS, Vinod CE, Saju SJ, Chebrolu B, Ponnusankar S. Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis. Ann Indian Acad Neurol 2021;24:155-63. [PMID: 34220057 DOI: 10.4103/aian.AIAN_1223_20] [Reference Citation Analysis]